You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SKF 81297 hydrobromide
Dopamine D1-like receptor agonist. Centrally active following systemic administration in vivo.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 370.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.7 mL||13.49 mL||26.98 mL|
|5 mM||0.54 mL||2.7 mL||5.4 mL|
|10 mM||0.27 mL||1.35 mL||2.7 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the biological activity of the product.
Arnt et al (1988) Relative DA D1 and D2 receptor affinity and efficacy determine whether DA agonists induce hyperactivity or oral stereotypy in rats. Pharmacol.Toxicol. 62 121 PMID: 3259694
Peacock et al (1990) The effects of DA D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur.J.Pharmacol. 186 49 PMID: 1980891
Reavill et al (1993) Pharmacological characterization of the discriminative stimulus properties of the DA D1 agonist, SKF 81297. Behav.Pharmacol. 4 135 PMID: 11224180
If you know of a relevant reference for SKF 81297 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: SKF 81297 hydrobromide, SKF 81297 hydrobromide supplier, D1, agonists, Dopamine, Receptors, D5, dopaminergic, SKF81297, hydrobromide, and, 1447, Tocris Bioscience
23 Citations for SKF 81297 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 81297 hydrobromide include:
Deng et al (2010) MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. PLoS One 13 1128 PMID: 20711186
Towers and Hestrin (2008) D1-like DA receptor activation modulates GABAergic inhibition but not electrical coupling between neocortical fast-spiking interneurons. J Neurosci 28 2633 PMID: 18322106
Stramiello (2008) D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology 55 871 PMID: 18644393
Floresco and Tse (2007) DArgic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci 27 2045 PMID: 17314300
Podleśny-Drabiniok et al (2017) Distinct retinoic acid receptor (RAR) isotypes control differentiation of embryonal carcinoma cells to dopaminergic or striatopallidal medium spiny neurons. Sci Rep 7 13671 PMID: 29057906
Liu et al (2017) A Sensitized IGF1 Treatment Restores Corticospinal Axon-Dependent Functions. Neuron 95 817 PMID: 28817801
Parnaudeau et al (2014) Glucocorticoid receptor gene inactivation in DA-innervated areas selectively decreases behavioral responses to amphetamine. Front Behav Neurosci 8 35 PMID: 24574986
Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Neurosci 7 624 PMID: 21785426
Pezze et al (2015) DArgic modulation of appetitive trace conditioning: the role of D1 receptors in medial prefrontal cortex. Mol Med Rep 232 2669 PMID: 25820982
Cilz et al (2014) DArgic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of α1 adrenoreceptors, inward rectifier K+, and T-type Ca2+ channels. Cereb Cortex 24 3195 PMID: 23843440
Södersten et al (2014) DA signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism. PLoS Genet 10 e1004574 PMID: 25254549
Spulber et al (2014) PFOS induces behavioral alterations, including spontaneous hyperactivity that is corrected by dexamfetamine in zebrafish larvae. PLoS One 9 e94227 PMID: 24740186
Chen et al (2014) Differential role of D1 and D2 receptors in the perifornical lateral hypothalamus in controlling ethanol drinking and food intake: possible interaction with local orexin neurons. Alcohol Clin Exp Res 38 777 PMID: 24236888
Olianas et al (2012) Coincidence signaling of DA D1-like and M1 muscarinic receptors in the regulation of cyclic AMP formation and CREB phosphorylation in mouse prefrontal cortex. Neurosignals 21 61 PMID: 22456324
Guha et al (2012) Stimulation of the D5 DA receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 122 823 PMID: 22639870
Saika (2018) Chemokine CXCL1 is responsible for cocaine-induced reward in mice. NeurosciPharm Reports 38 145 PMID: 30175527
Beckley et al (2016) The First Alcohol Drink Triggers mTORC1-Dependent Synaptic Plasticity in Nucleus Accumbens DA D1 Receptor Neurons. J Neurosci 36 701 PMID: 26791202
Hodas et al (2012) DArgic modulation of the hippocampal neuropil proteome identified by bioorthogonal noncanonical amino acid tagging (BONCAT). Proteomics 12 2464 PMID: 22744909
Krishnan et al (2011) DA-induced plasticity, phospholipase D (PLD) activity and cocaine-cue behavior depend on PLD-linked metabotropic glutamate receptors in amygdala. PLoS One 6 e25639 PMID: 21980514
Li et al (2011) Casein kinase 1 enables nucleus accumbens amphetamine-induced locomotion by regulating AMPA receptor phosphorylation. J Neurochem 118 237 PMID: 21564097
Guo (2017) DA D4 receptor activation restores CA1 LTP in hippocampal slices from aged mice. Aging Cell 16 1323 PMID: 28975698
Meunier et al (2015) Effect of DArgic D1 receptors on plasticity is dependent of serotoninergic 5-HT1A receptors in L5-pyramidal neurons of the prefrontal cortex. PLoS One 10 e0120286 PMID: 25775449
Marley et al (2013) GPR88 reveals a discrete function of primary cilia as selective insulators of GPCR cross-talk. Psychopharmacology (Berl) 8 e70857 PMID: 23936473
Do you know of a great paper that uses SKF 81297 hydrobromide from Tocris? Please let us know.
Reviews for SKF 81297 hydrobromide
Average Rating: 5 (Based on 1 Review.)
Have you used SKF 81297 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
We used SKF81297 at a concentration of 10 µM/L to active dopamine D1 receptor in cultured mouse striatal neuron.
It is very easy to dissolve the product
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.